Evidence map›Paper›PMID 41498022›Full record

ArticleMediators of inflammation2025

Development and Evaluation of an Innovative Inflammatory Prognostic Score for Predicting Long-Term Mortality in Patients With Pulmonary Embolism.

Ning Zhu, Lei Zhang, Jiabao Wu, Fei Ye, Nanding Yu, Chao Cao, Limin Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mediators of inflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ning ZhuDepartment of Respiratory and Critical Care Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, China, fjmu.edu.cn.ORCID https://orcid.org/0000-0001-5902-0602
Lei ZhangDepartment of Respiratory and Critical Care Medicine, The Affiliated People Hospital of Ningbo University, Ningbo, China, nbu.edu.cn.
Jiabao WuDepartment of Respiratory and Critical Care Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, China, fjmu.edu.cn.
Fei YeDepartment of Respiratory and Critical Care Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, China, fjmu.edu.cn.
Nanding YuDepartment of Respiratory and Critical Care Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, China, fjmu.edu.cn.
Chao CaoDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Ningbo University, Ningbo, China, nbu.edu.cn.
Limin ChenDepartment of Respiratory and Critical Care Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, China, fjmu.edu.cn.ORCID https://orcid.org/0000-0003-1554-4951

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Systemic inflammation is closely associated with adverse outcomes in pulmonary embolism (PE). This study aimed to develop and evaluate a novel inflammatory prognostic score (IPS) derived from multiple inflammation-related biomarkers to predict long-term all-cause mortality in patients with acute PE. Methods: This retrospective cohort study included 1642 patients with confirmed acute PE admitted between January 2016 and January 2024 at the First Affiliated Hospital of Ningbo University and the Affiliated People Hospital of Ningbo University. The primary outcome was all-cause mortality. Follow-up was conducted in January 2025. Fifteen inflammatory biomarkers were analyzed, including C-reactive protein (CRP), white blood cell count (WBC), neutrophil count (NEU), lymphocyte count (LYM), monocyte count (MON), red cell distribution width (RDW), platelet count (PLT), and eight derived indices: neutrophil-to-lymphocyte ratio (NLR), derived NLR (dNLR), monocyte-to-lymphocyte ratio (MLR), neutrophil-MLR (NMLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and inflammatory burden index (IBI). IPS was constructed using least absolute shrinkage and selection operator (LASSO) Cox regression. Prognostic performance was assessed using Kaplan-Meier survival analysis, multivariable Cox regression, time-dependent receiver operating characteristic (ROC) analysis, and random survival forest (RSF). Results: During a median follow-up of 43.87 months, 262 patients (16.0%) died. The IPS was calculated as: IPS = 0.395 × IBI + 0.236 × RDW + 0.208 × SIRI + 0.115 × MLR + 0.040 × CRP. Patients with high IPS (≥0.55) had a significantly higher risk of all-cause mortality compared to those with low IPS (adjusted hazard ratio [HR] = 2.55, 95% confidence intervals [CI]: 1.92-3.38; Conclusions: The IPS, derived from five routinely available inflammatory biomarkers, was independently associated with long-term mortality and significantly enhanced risk stratification beyond traditional clinical predictors in patients with acute PE. This score may support early prognostic assessment and individualized management.

Indexed as

InflammationPulmonary EmbolismAgedBiomarkersC-Reactive ProteinFemaleHumansKaplan-Meier EstimateLeukocyte CountLymphocytesMaleMiddle AgedMonocytesNeutrophilsPlatelet CountPrognosisBiomarkersC-Reactive Proteinacute pulmonary embolismall-cause mortalitybiomarkersinflammationinflammatory prognostic scoring (IPS)

Identifiers

PMID41498022
PMCPMC12767386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.